Each 5 ml vial contains Etoposide BP 100 mg, Benzyl Alcohol IP 150 mg, Ethyl Alcohol IP 30.5% v/v in a sterile nonaqueous vehicle
Each soft gelatin capsule contains Etoposide BP 50 mg
Without a Prescription
Etoposide is prescribed for the treatment of:
Etoposide is prescribed in the management of small-cell lung carcinoma and testicular tumours.
It is prescribed for Hodgkins’ and non-Hodgkins’ lymphoma, acute leukemia and trophoblastic disease.
Precautions for administration
Etoposide Injection should not be given by rapid intravenous injection.
Skin reactions may occur with accidental exposure.
Use of gloves is recommended.
If solution contacts the skin or mucosa, the area should be thoroughly washed with soap and water.
Preparation for intravenous administration
Etoposide may be diluted with either 5 per cent dextrose injection or 0.9 percent sodium chloride injection to give a final concentration of 0.2 or 0.4 mg/mL.
The solution should be administered over 30 to 60 minutes or longer.
The dosage of Etoposide must be based on the clinical and haematological response and tolerance of the patient and whether or not chemotherapy or radiation therapy has been or is being used in order to obtain optimum therapeutic results with minimum side effects.
A repeat course of Etoposide should not be administered until the patient’s haematologic function is within acceptable limits.
The usual dose of Etoposide in combination with other approved chemo-therapeutic agents ranges from 50 to 100 mg/m 2 /day on days one through five to 100 mg/m 2 /day on days one, three and five.
Chemotherapy courses are repeated at three to four week intervals after adequate recovery from any toxicity.
The recommended dose is twice the intravenous dose.
Etoposide is contraindicated if you have any of the following conditions:
Hypersensitivity to the components of the formulation.
- Vial of 5 ml;
- Container of 4 capsules;